Further studies with larger sample sizes, especially related to patients with BRAF V600E mutations, more comprehensive genomic and methylation -based profiling, and longer follow-up periods are needed to extend these findings and explore other potential prognostic markers in pediatric high-grade glioma. This evidence concerns the gene BRAF and central nervous system cancer.